Filana Therapeutics, Inc. (FLNA) Stock Analysis & Investment Frameworks
Filana Therapeutics, Inc. (FLNA) stock analysis on Invetso. Review Filana Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Filana Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Filana Therapeutics, Inc. Key Financial Metrics
- Market Cap: $33.98M
- Revenue: $N/A
- ROE: -58.78%
- ROIC: -72.12%
- Dividend Yield: N/A
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Filana Therapeutics, Inc. Investment Frameworks
Invetso analyzes Filana Therapeutics, Inc. (FLNA) across the following frameworks:
- Filana Therapeutics, Inc. 10Y Growth Potential
- Filana Therapeutics, Inc. Scenario Analysis
- Filana Therapeutics, Inc. Risks & Opportunities
- Filana Therapeutics, Inc. Economic Moat
- Filana Therapeutics, Inc. Business Model
- Filana Therapeutics, Inc. Management
- Filana Therapeutics, Inc. SWOT Analysis
- Filana Therapeutics, Inc. Porter's 5 Forces
- Filana Therapeutics, Inc. PESTLE Analysis
- Filana Therapeutics, Inc. ESG Analysis